Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_2_suppst2.pdf
Signature-based analysis of MET proto-oncogene mutations using DHPLC.
Nickerson ML et al.
Human Mutation, 2000
Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L et al.
Oncogene, 1999
Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours.
Fischer J et al.
Oncogene, 1998
Select a paper to view details